DUBLIN--(BUSINESS WIRE)--The "Progressive Multifocal Leukoencephalopathy - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
Progressive Multifocal Leukoencephalopathy - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Progressive Multifocal Leukoencephalopathy (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Progressive Multifocal Leukoencephalopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 5 and 3 respectively.
Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Progressive Multifocal Leukoencephalopathy (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Progressive Multifocal Leukoencephalopathy (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Progressive Multifocal Leukoencephalopathy (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Progressive Multifocal Leukoencephalopathy (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Progressive Multifocal Leukoencephalopathy (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Progressive Multifocal Leukoencephalopathy (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
Introduction
Progressive Multifocal Leukoencephalopathy - Overview
Progressive Multifocal Leukoencephalopathy - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
Progressive Multifocal Leukoencephalopathy - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
Progressive Multifocal Leukoencephalopathy - Companies Involved in Therapeutics Development
- Biological E Ltd
- Evrys Bio
- Excision BioTherapeutics Inc
- Genexine Inc
- Humabs BioMed SA
- Inhibikase Therapeutics Inc
- Neurimmune Holding AG
- Pomona Ricerca SRL
Progressive Multifocal Leukoencephalopathy - Drug Profiles
EBT-103 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
efineptakin alfa - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
IkT-01427 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
Monoclonal Antibody for John Cunningham Infections and Progressive Multifocal Leukoencephalopathy - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
NI-307 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
PNJC-1 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
Small Molecules to Activate Sirtuin for Viral Infections - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
Vaccine for Progressive Multifocal Leukoencephalopathy - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
Progressive Multifocal Leukoencephalopathy - Dormant Projects
Progressive Multifocal Leukoencephalopathy - Product Development Milestones
- Featured News & Press Releases
- Jun 15, 2020: NeoImmuneTech receives FDA orphan drug designation for NT-I7 (efineptakin alfa) for the treatment of progressive multifocal leukoencephalopathy
Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/m1uocr
